At the news
? BULLISHIMPACT 8/10 8-K filed Apr 2, 2026 at 08:45 ET
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date of September 19, 2026. This marks a key regulatory milestone for a potential first-in-class therapy for a rare and severe pediatric neurodegenerative disease.
- FDA accepted resubmitted BLA for UX111 (rebisufligene etisparvovec) for accelerated approval
- Indication: Sanfilippo syndrome Type A (MPS IIIA), a rare pediatric neurodegenerative disorder
- PDUFA action date set for September 19, 2026
- Therapy is an AAV9 gene therapy, representing a potential one-time treatment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access